2026 ACC/AHA Dyslipidemia Guideline

<p>When should apoB be measured? In whom should lipoprotein(a) be measured? Should LDL-C be calculated by the Friedewald, Martin-Hopkins, or Sampson-NIH equations? How do the PREVENT-ASCVD equations differ from the Pooled Cohort Equations? How long is a coronary artery calcium (CAC) score of 0 &quot;good for&quot;? How should CAC scoring be used to guide statin initiation and intensity? What are the new LDL-C, non-HDL-C, and apoB targets for secondary prevention? What counts as &quot;very high-risk&quot; ASCVD, and how does treatment differ? In which patients should bempedoic acid, inclisiran, or olezarsen be added? Watch for answers to these key questions and more in this &quot;deep dive&quot; of the 2026 ACC/AHA Guideline on the Management of Dyslipidemia. </p><p><br></p><p>Watch on YouTube: https://youtu.be/yHXL_dH8zCo</p><p><br></p><p>Difficulty Level: Easy</p><p><br></p><p>You are listening to Hu Said: Guideline Lifeline</p><p>Please subscribe, rate, and support the channel! Ads help keep materials free for everyone.</p><p>More MedEd resources available at <a href="https://www.rueyhu.com" target="_blank" rel="ugc noopener noreferrer">⁠⁠⁠⁠www.rueyhu.com⁠⁠⁠⁠</a></p><p>Updates at Twitter/X: <a href="https://twitter.com/ruey_hu" target="_blank" rel="ugc noopener noreferrer">⁠⁠⁠⁠@Ruey_Hu⁠</a></p>